224 related articles for article (PubMed ID: 30250538)
21. The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients.
Dal Bello MG; Filiberti RA; Alama A; Orengo AM; Mussap M; Coco S; Vanni I; Boccardo S; Rijavec E; Genova C; Biello F; Barletta G; Rossi G; Tagliamento M; Maggioni C; Grossi F
J Transl Med; 2019 Mar; 17(1):74. PubMed ID: 30849967
[TBL] [Abstract][Full Text] [Related]
22. Quantification of circulating cell-free DNA to predict patient survival in non-small-cell lung cancer.
Hyun MH; Sung JS; Kang EJ; Choi YJ; Park KH; Shin SW; Lee SY; Kim YH
Oncotarget; 2017 Nov; 8(55):94417-94430. PubMed ID: 29212238
[TBL] [Abstract][Full Text] [Related]
23. [Clinical value of CEA and CYFRA21-1 as an assessment indicator of therapeutic efficacy in advanced non-small cell lung cancer patients].
Li L; Song LH; Ding SC; Zhang XJ; Qiang L; Han CY; Yuan XT; Xu DD
Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):850-4. PubMed ID: 21223692
[TBL] [Abstract][Full Text] [Related]
24. The relationship between Glasgow Prognostic Score and serum tumor markers in patients with advanced non-small cell lung cancer.
Jiang AG; Chen HL; Lu HY
BMC Cancer; 2015 May; 15():386. PubMed ID: 25956656
[TBL] [Abstract][Full Text] [Related]
25. A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial.
Yanagita M; Redig AJ; Paweletz CP; Dahlberg SE; O'Connell A; Feeney N; Taibi M; Boucher D; Oxnard GR; Johnson BE; Costa DB; Jackman DM; Jänne PA
Clin Cancer Res; 2016 Dec; 22(24):6010-6020. PubMed ID: 27281561
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic value of combined detection of plasma cfDNA concentration and integrity in NSCLC.
Ren S; Yu C; Huang Q
Lung Cancer Manag; 2024; 13(1):LMT64. PubMed ID: 38812772
[TBL] [Abstract][Full Text] [Related]
27. Plasma cell-free DNA levels and integrity in patients with chest radiological findings: NSCLC versus benign lung nodules.
Szpechcinski A; Rudzinski P; Kupis W; Langfort R; Orlowski T; Chorostowska-Wynimko J
Cancer Lett; 2016 May; 374(2):202-7. PubMed ID: 26854716
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic value of Cyfra21-1, SCC and CEA for differentiation of early-stage NSCLC from benign lung disease.
Chen F; Wang XY; Han XH; Wang H; Qi J
Int J Clin Exp Med; 2015; 8(7):11295-300. PubMed ID: 26379938
[TBL] [Abstract][Full Text] [Related]
29. Circulating cell-free DNA variables as marker of ovarian cancer patients: A pilot study.
Stamenkovic S; Cheng J; Surowy H; Burwinkel B; Gündert M
Cancer Biomark; 2020; 28(2):159-167. PubMed ID: 32176629
[TBL] [Abstract][Full Text] [Related]
30. Serum Sialyl Lewis x and cytokeratin 19 fragment as predictive factors for recurrence in patients with stage I non-small cell lung cancer.
Mizuguchi S; Nishiyama N; Iwata T; Nishida T; Izumi N; Tsukioka T; Inoue K; Uenishi T; Wakasa K; Suehiro S
Lung Cancer; 2007 Dec; 58(3):369-75. PubMed ID: 17697728
[TBL] [Abstract][Full Text] [Related]
31. Serum circulating free DNA of syncytin-1 as a novel molecular marker for early diagnosis of non-small-cell lung cancer.
Zhuang X; Qian J; Xia X; Wang Y; Wang H; Jing L; Zhang Y; Zhang Y
Biomark Med; 2022 Dec; 16(18):1259-1268. PubMed ID: 36861469
[No Abstract] [Full Text] [Related]
32. Low expression of miR-27b in serum exosomes of non-small cell lung cancer facilitates its progression by affecting EGFR.
Cao X; Zhong W; Guo S; Zhang Z; Xie C
Open Med (Wars); 2022; 17(1):816-825. PubMed ID: 35582197
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic and prognostic value of serum CircERBB2 level in NSCLC and its correlation with clinicopathological features in NSCLC patients.
Zou G; Lu W; Dai X
Am J Transl Res; 2023; 15(2):1215-1222. PubMed ID: 36915755
[TBL] [Abstract][Full Text] [Related]
34. Comparison of Serum MicroRNA21 and Tumor Markers in Diagnosis of Early Non-Small Cell Lung Cancer.
Sun M; Song J; Zhou Z; Zhu R; Jin H; Ji Y; Lu Q; Ju H
Dis Markers; 2016; 2016():3823121. PubMed ID: 26880855
[TBL] [Abstract][Full Text] [Related]
35. Circulating long noncoding RNA act as potential novel biomarkers for diagnosis and prognosis of non-small cell lung cancer.
Xie Y; Zhang Y; Du L; Jiang X; Yan S; Duan W; Li J; Zhan Y; Wang L; Zhang S; Li S; Wang L; Xu S; Wang C
Mol Oncol; 2018 May; 12(5):648-658. PubMed ID: 29504701
[TBL] [Abstract][Full Text] [Related]
36. Clinical utility of liquid biopsy in canine oral malignant melanoma using cell-free DNA.
Tagawa M; Aoki M
Front Vet Sci; 2023; 10():1182093. PubMed ID: 37408834
[TBL] [Abstract][Full Text] [Related]
37. Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value.
Alegre E; Fusco JP; Restituto P; Salas-Benito D; Rodríguez-Ruiz ME; Andueza MP; Pajares MJ; Patiño-García A; Pio R; Lozano MD; Gúrpide A; Lopez-Picazo JM; Gil-Bazo I; Perez-Gracia JL; Gonzalez A
Tumour Biol; 2016 Oct; 37(10):13687-13694. PubMed ID: 27473086
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer.
Matsuoka K; Sumitomo S; Nakashima N; Nakajima D; Misaki N
Eur J Cardiothorac Surg; 2007 Sep; 32(3):435-9. PubMed ID: 17611117
[TBL] [Abstract][Full Text] [Related]
39. Quantification of plasma cell-free DNA levels in dogs with various tumors.
Tagawa M; Shimbo G; Inokuma H; Miyahara K
J Vet Diagn Invest; 2019 Nov; 31(6):836-843. PubMed ID: 31585514
[TBL] [Abstract][Full Text] [Related]
40. Predictive value of serum SCCA and CYFRA21-1 levels on radiotherapy efficacy and prognosis in patients with non-small cell lung cancer.
Chen F; Zhang X
Biotechnol Genet Eng Rev; 2023 May; ():1-10. PubMed ID: 37153975
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
